Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer

Pemetrexed (PEM) improves the overall survival of patients with advanced non-small cell lung cancer (NSCLC) when administered as maintenance therapy. However, PEM resistance often appears during the therapy. Although thymidylate synthase is known to be responsible for PEM resistance, no other mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanino, Ryosuke, Tsubata, Yukari, Harashima, Nanae, Harada, Mamoru, Isobe, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908287/
https://www.ncbi.nlm.nih.gov/pubmed/29682186
http://dx.doi.org/10.18632/oncotarget.24704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908287/
https://www.ncbi.nlm.nih.gov/pubmed/29682186
http://dx.doi.org/10.18632/oncotarget.24704

Ejemplares similares